Skip to main content
. 2019 Dec 18;5(12):eaax9586. doi: 10.1126/sciadv.aax9586

Table 4. TEAEs by preferred term—safety population.

Note that each individual was only counted once per preferred term.

Preferred term Vehicle (n = 8) SYNT001
(1 mg/kg) (n = 6)
SYNT001
(3 mg/kg) (n = 6)
SYNT001
(10 mg/kg) (n = 6)
SYNT001
(30 mg/kg) (n = 5)
Pooled SYNT001
(n = 23)
Individuals with ≥1 TEAE, n (%) 1 (12.5) 0 0 3 (50.0) 5 (100) 8 (34.8)
Headache 0 0 0 3 (50.0) 5 (100) 8 (34.8)
Chills 1 (12.5) 0 0 0 1 (20.0) 1 (4.3)
Presyncope 0 0 0 1 (16.7) 0 1 (4.3)
Fatigue 0 0 0 1 (16.7) 0 1 (4.3)
Pyrexia 0 0 0 1 (16.7) 0 1 (4.3)
Abdominal pain 0 0 0 0 1 (20.0) 1 (4.3)
Diarrhea 0 0 0 0 1 (20.0) 1 (4.3)
Nausea 0 0 0 0 1 (20.0) 1 (4.3)
Arthralgia 0 0 0 1 (16.7) 0 1 (4.3)
Muscular weakness 0 0 0 1 (16.7) 0 1 (4.3)
Myalgia 0 0 0 1 (16.7) 0 1 (4.3)
Lacrimation increased 0 0 0 1 (16.7) 0 1 (4.3)
Decreased appetite 0 0 0 0 1 (20.0) 1 (4.3)
Rhinorrhea 0 0 0 1 (16.7) 0 1 (4.3)